Average Co-Inventor Count = 7.42
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Vtv Therapeutics LLC (16 from 52 patents)
2. Transtech Pharma, Inc. (9 from 49 patents)
3. Novo Nordisk A/s (5 from 1,777 patents)
4. High Point Pharmaceuticals, LLC (4 from 50 patents)
34 patents:
1. 12091407 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
2. 11649230 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
3. 11130753 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
4. 10889580 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
5. 10570126 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
6. 10568888 - Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
7. 10391097 - Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
8. 10287284 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
9. 10085990 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
10. 10030011 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
11. 9833457 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
12. 9687489 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
13. 9393245 - Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
14. 9175003 - Substituted azoanthracene derivatives and intermediates for preparation thereof
15. 9163022 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors